Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single IV dose PF-06823859 in Japanese healthy adults
jRCT2031210368Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dazukibart (3 arms), sponsored by Pfizer. Primary endpoints: Assessments of adverse events and serious adverse events, ECG QT interval and 7 more. Started Sep 2021; status: completed.
02
Drugs
dazukibart
Beyond the preview
Go deeper on jRCT2031210368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210368.